Back to Search
Start Over
Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-d-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy
- Source :
- Molecular Imaging and Biology. 23:139-147
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- We investigated the ability of baseline 2-deoxy-2-[18F]fluoro-d-glucose PET/CT parameters, acquired before the start of immunotherapy, to predict development of hyperprogressive disease (HPD) in melanoma patients. We also evaluated the diagnostic performances of ratios of baseline and first restaging PET/CT parameters to diagnose HPD without information of the tumor growth kinetic ratio (TGKR) that requires pre-baseline imaging before baseline imaging (3 timepoint imaging). Seventy-six patients who underwent PET/CT before and approximately 3 months following initiation of immunotherapy were included. PET/CT parameters, including metabolic tumor volume (MTV) for all melanoma lesions and total measured tumor burden (TMTB) based on irRECIST, were measured from baseline PET/CT (MTVbase and TMTBbase) and first restaging PET/CT (MTVpost and TMTBpost). The ratios of MTV (MTVpost/MTVbase, MTVr) and TMTB (TMTBpost/TMTBbase, TMTBr) were calculated. MTVbase of HPD patients (n = 9, TGKR ≥ 2) was larger than that of non-HPD (n = 67, TGKR
- Subjects :
- 2 deoxy 2 18f fluoro d glucose
Cancer Research
PET-CT
business.industry
medicine.medical_treatment
Melanoma
Area under the curve
Disease
Metabolic tumor volume
Immunotherapy
medicine.disease
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Oncology
medicine
Radiology, Nuclear Medicine and imaging
Tumor growth
Nuclear medicine
business
Subjects
Details
- ISSN :
- 18602002 and 15361632
- Volume :
- 23
- Database :
- OpenAIRE
- Journal :
- Molecular Imaging and Biology
- Accession number :
- edsair.doi...........d69a6cf58ede464fead5cea1acd067b6